Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of 3beta,23-O-isopropylidene hydroxyl betulinic acid in preparation of medicine for treating non-alcoholic steatohepatitis

A propylidene hydroxyl, steatohepatitis technology, applied in the field of medicine to achieve the effect of reducing lipid accumulation

Active Publication Date: 2022-02-18
DONGZHIMEN HOSPITAL OF BEIJING UNIV OF CHINESE MEDICINE +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that 3α, 23-O-isopropylidene-3α, 23-dihydroxylupine acid has significant anticancer activity, but it has not been involved in the treatment of NASH, see literature Valencia-Chan, Lia S.; Garcia- Camara, Isabel; Torres-Tapia, et al.Lupane-Type Triterpenes of Phoradendron vernicosum[J].J.Nat.Prod.2017,80(11):3038-3042

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 3beta,23-O-isopropylidene hydroxyl betulinic acid in preparation of medicine for treating non-alcoholic steatohepatitis
  • Application of 3beta,23-O-isopropylidene hydroxyl betulinic acid in preparation of medicine for treating non-alcoholic steatohepatitis
  • Application of 3beta,23-O-isopropylidene hydroxyl betulinic acid in preparation of medicine for treating non-alcoholic steatohepatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1 Preparation of 3β, 23-O-isopropylidene hydroxybetulinic acid (7C)

[0035] The reaction product of 23-hydroxybetulinic acid (130mg, 0.28mmol) and 2,2-dimethoxypropane analog (258mg, 2.48mmol) in acidic acetone solution. All the above-mentioned participating reaction principles can be obtained commercially. The reaction was carried out at room temperature and monitored by TLC until the starting point disappeared. After spin-drying, water was added and extracted with DCM to obtain 140 mg of white solid (7C). The relevant NMR data of 7C are shown in Table 1.

[0036] Table 1. 1 H and 13 C NMR Data for 7C in pyridine-d 5 .(NMR data were measured at 600MHz for 1 H NMR and at 150MHz for 13 C NMR. The assignments were based on 1 H- 1 H COZY, HSQC, and HMBC experiments.)

[0037]

[0038]

Embodiment 2

[0039] Example 2 The inhibitory effect of 3β,23-O-isopropylidene hydroxybetulinic acid (7C) on protein levels and mRNA of liver fibrosis-related markers was detected by Western Blot and Real time-PCR.

[0040] 1. Use DMEM (Gibco) medium containing 10% fetal bovine serum, at 37°C, 5% CO 2 LX-2 cells were cultured under these conditions. According to each well 3×10 5 After 24 hours of culture, remove the original medium and add serum-free DMEM medium, and starve for 24 hours. Then add the stimulating factor TGF-β1 (2ng / mL) to induce, and add different concentrations of compound 7C at the same time. (Induction by addition of TGF-β1 only).

[0041] 2. After continuing to culture for 24 hours, add 0.2mL RIPA lysate to the 6-well plate to extract the protein, and use the BCA method to determine the protein concentration. The sample was loaded at 25 μg per well, and after electrophoresis, membrane transfer, blocking with 5% skim milk, and antibody incubation, the desired protein ...

Embodiment 3

[0044] Example 3 Preparation of NASH model in choline-combined methionine-deficient high-fat diet (CDAHFD) mice

[0045] CDAHFD-induced mouse NASH model: C57BL / 6N mice (6 weeks old) were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., and allowed to adapt to feeding for one week before starting the experiment. All mice were randomly divided into the following four groups: (1) SD group (n=7), fed with standard diet (SD) for 12 weeks; (2) CDAHFD group (n=7), fed with CDAHFD (A06071302, purchased from Research Diets, New Brunswick, USA) diet for 12 weeks; (3) 7C-50 group (n=7), fed with CDAHFD diet for 8 weeks, followed by intraperitoneal injection of 7C (50mg / kg) every day for 4 weeks; (4) 7C-100 Group (n=7), fed CDAHFD diet for 8 weeks, followed by oral administration of 7C (100 mg / kg) every day for 4 weeks. After 12 weeks, the mice were weighed and sacrificed under isoflurane anesthesia by bleeding. Blood samples were collected and stored at -8...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of 3beta,23-O-isopropylidene hydroxyl betulinic acid in preparation of a medicine for treating non-alcoholic steatohepatitis, and discloses application of the 3beta,23-O-isopropylidene hydroxyl betulinic acid in preparation of the medicine for treating non-alcoholic steatohepatitis for the first time. Experiments prove that the 3beta,23-O-isopropylidene hydroxyl betulinic acid can significantly reduce lipid accumulation, inflammation and hepatic fibrosis of experimental NASH, and has important value in treatment of non-alcoholic steatohepatitis.

Description

technical field [0001] The invention belongs to the field of medicine and relates to the application of 3β, 23-O-isopropylidene hydroxybetulinic acid in the preparation of medicines for treating nonalcoholic steatohepatitis. Background technique [0002] Nonalcoholic fatty liver disease (NAFLD) affects at least a quarter of the adult population worldwide and is by far the most common chronic liver disease. Nonalcoholic steatohepatitis (NASH) is a progressive form of NAFLD associated with persistent hepatocellular injury that can lead to liver fibrosis and even progress to cirrhosis and end-stage liver disease. Although there has been a lot of progress in the basic and clinical research and understanding of nonalcoholic steatohepatitis in recent years, there are no specific and effective chemical drugs and biological agents, especially in the treatment of liver fibrosis (Chinese Medical Association Hepatology Branch, Digestive Disease Branch of Chinese Medical Association, I...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/56A61P1/00A61P29/00
CPCA61K31/56A61P1/00A61P29/00
Inventor 林生武玉卓张娜何红伟夏桂阳夏欢李晋玉王玲燕
Owner DONGZHIMEN HOSPITAL OF BEIJING UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com